NEW YORK, Aug. 8, 2022 /PRNewswire/ -- The Uveitis Drugs Market report has been added to Technavio's offering. With ISO 9001:2015 certification, Technavio is proudly partnering with more than 100 Fortune 500 companies for over 16 years.
The potential growth difference for the uveitis drugs market between 2021 and 2026 is USD 269.65 million. The market for uveitis medications is growing significantly because of the rising frequency of eye problems and related risk factors for uveitis, while some factors, such as the unfavorable side effects of corticosteroids, may restrain market expansion. To get the exact yearly growth variance and the Y-O-Y growth rate, Talk to our analyst.
Key Market Dynamics:
The increased frequency of eye conditions and related uveitis risk factors is one of the main factors boosting the global market for uveitis medications. Multifactorial etiologies for uveitis include immune system attacks, infections, and tumors that can develop inside the eye or in other regions of the body.
In addition, bruising in and around the eye as well as chemicals that can enter the eye could also contribute to the illness. During the projection period, the prevalence of various risk factors such as hepatitis, Bechet's syndrome, CMV retinitis, psoriasis, and ulcerative colitis will propel the market's expansion. Although factors such as adverse effects of corticosteroids may impede the market growth.
To learn about additional key drivers, trends, and challenges available with
Technavio. Read FREE Sample Report right now!
North America will account for 43% of market growth. The main markets in North America for uveitis medications are the US and Canada. The market in this region will grow more quickly than the markets in ROW and Europe.
The expansion of the uveitis medicines market in North America over the projected period would be aided by the notable increase in sales of approved drugs for the treatment of uveitis and the rising incidence of many risk factors for the illness.
Download our sample report for additional insights into the contribution of all the
segments, and regional opportunities in the report.
Key Market Vendors
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
To gain access to more vendor profiles with their key offerings available with
Technavio, Click Here
Mental Health Market by Service and Geography - Forecast and Analysis 2022-2026: The mental health market share is expected to increase to USD 201.41 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 9.06%.
Raloxifene Hydrochloride Market by End-user and Geography - Forecast and Analysis 2022-2026: The raloxifene hydrochloride market share is expected to increase to USD 502.78 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.11%.
Uveitis Drugs Market Scope
Growth momentum & CAGR
Accelerate at a CAGR of 5.9%
Market growth 2022-2026
$ 269.65 million
YoY growth (%)
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 43%
Key consumer countries
US, Canada, Germany, UK, and China
Leading companies, Competitive Strategies, Consumer engagement scope
Key companies profiled
AbbVie Inc., Alimera Sciences Inc., Amgen Inc., Aurobindo Pharma Ltd., Bausch Health Companies Inc., Biogen Inc., Cadila Pharmaceuticals Ltd., EyePoint Pharmaceuticals Inc., Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc, Johnson and Johnson, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Sebela Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Browse for Technavio "Health Care" Research Reports
Table of Contents
1 Executive Summary
1.1 Market Overview
2 Market Landscape
2.1 Market ecosystem
3 Market Sizing
3.1 Market Definition
3.2 Market segment analysis
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
4 Five Forces Analysis
4.1 Five forces summary
4.2 Bargaining power of buyers
4.3 Bargaining power of suppliers
4.4 Threat of new entrants
4.5 Threat of substitutes
4.6 Threat of rivalry
4.7 Market condition
5 Market Segmentation by Product
5.1 Market segments
5.2 Comparison by Product
5.3 Small molecules - Market size and forecast 2021-2026
5.4 Biologics - Market size and forecast 2021-2026
5.5 Market opportunity by Product
6 Customer Landscape
6.1 Customer landscape overview
7 Geographic Landscape
7.1 Geographic segmentation
7.2 Geographic comparison
7.3 North America - Market size and forecast 2021-2026
7.4 Europe - Market size and forecast 2021-2026
7.5 Asia - Market size and forecast 2021-2026
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
7.7 US - Market size and forecast 2021-2026
7.8 Germany - Market size and forecast 2021-2026
7.9 UK - Market size and forecast 2021-2026
7.10 Canada - Market size and forecast 2021-2026
7.11 China - Market size and forecast 2021-2026
7.12 Market opportunity by geography
8 Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
8.4 Market trends
9 Vendor Landscape
9.2 Vendor landscape
9.3 Landscape disruption
9.4 Industry risks
10 Vendor Analysis
10.1 Vendors covered
10.2 Market positioning of vendors
10.3 AbbVie Inc.
10.4 Alimera Sciences Inc.
10.5 Amgen Inc.
10.6 Biogen Inc.
10.7 Cadila Pharmaceuticals Ltd.
10.8 EyePoint Pharmaceuticals Inc.
10.9 Johnson and Johnson
10.10 Novartis AG
10.11 Pfizer Inc.
10.12 Regeneron Pharmaceuticals Inc.
11.1 Scope of the report
11.2 Inclusions and exclusions checklist
11.3 Currency conversion rates for US$
11.4 Research methodology
11.5 List of abbreviations
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View original content to download multimedia:https://www.prnewswire.com/news-releases/uveitis-drugs-market-high-prevalence-of-eye-disorders-and-associated-risk-factors-of-uveitis-to-boost-market-growth---technavio-301600768.html